Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | CCKBR | P32239 | 11/20 | 0.55 |
| ▸ | CCKAR | P32238 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emideltide SCHEMBL5523007 | 1.00 | NPBWR1 (0.57) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| Emideltide SCHEMBL29533932 | 1.00 | NPBWR1 (0.57) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| SCHEMBL29505141 | 0.94 | OPRD1 (0.65) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| SCHEMBL31753881 | 0.88 | PRMT1 (0.59) | NPBWR1OPRD1OPRM1PRMT1 | |
| SCHEMBL10749608 | 0.88 | OPRD1 (0.68) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| SCHEMBL29638053 | 0.87 | CCKBR (0.60) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| SCHEMBL31031505 | 0.87 | ERAP2 (0.59) | NPBWR1OPRD1OPRM1 | |
| SCHEMBL30777843 | 0.87 | OPRD1 (0.70) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| SCHEMBL29505086 | 0.87 | OPRD1 (0.73) | NPBWR1OPRD1OPRM1CCKBRCCKAR | |
| SCHEMBL31127539 | 0.86 | PRMT1 (0.55) | OPRD1OPRM1CCKBRCCKARPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-05-15 | — | — | US | claimed |
| US-20250032581-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-01-30 | — | — | US | claimed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118865118-A | Method for identifying tower pole in foggy weather and related products | 国网四川省电力公司超高压分公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2023201303-A2 | SYSTEMS AND METHODS TO AUTOMATICALLY ADMINISTER A PSYCHOACTIVE SUBSTANCE TO AN AIRWAY OF A USER BASED ON A DETECTED EVENT OR CONDITION | Green Sky Creations, LLC (US) | 2023-10-19 | — | — | WO | claimed |
| US-11670410-B1 | Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition | Green Sky Creations LLC (US) | 2023-06-06 | — | — | US | claimed |
| CN-116114045-A | Circuit breaker, detachable display for a circuit breaker and electronic triggering unit | 西门子股份公司 | 2023-05-12 | — | — | CN | claimed |
| EP-4165670-A1 | CIRCUIT BREAKER, REMOVABLE DISPLAY, AND ELECTRONIC TRIGGER UNIT FOR A CIRCUIT BREAKER | Siemens Aktiengesellschaft (DE) | 2023-04-19 | — | — | EP | claimed |
| EP-2440184-B1 | DIKETOPIPERAZINE MICROPARTICLES WITH DEFINED SPECIFIC SURFACE AREAS | MANNKIND CORP (US) | 2023-04-05 | — | — | EP | claimed |
| EP-3587404-B1 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF | MANNKIND CORP (US) | 2022-07-13 | — | — | EP | claimed |
| CN-114010759-B | Short peptide gel with sleep improvement effect and preparation method and application thereof | 安域生物科技(杭州)有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| CN-112272227-B | Edge computing task scheduling method based on computation graph | 华侨大学 | 2022-04-15 | — | — | CN | claimed |
| WO-2022042980-A1 | CIRCUIT BREAKER, REMOVABLE DISPLAY, AND ELECTRONIC TRIGGER UNIT FOR A CIRCUIT BREAKER | SIEMENS AKTIENGESELLSCHAFT (DE) | 2022-03-03 | — | — | WO | claimed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | claimed |
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | MANNKIND CORPORATION (US) | 2026-05-28 | — | — | US | disclosed |
| CN-114978116-B | Preparation method of radiation-resistant fault-tolerant trigger | FUDAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6613738-B1 | Comprising 1,2-dihydroxy-homotyrosine, 4-hydroxyproline, threonine, glutamine, 3-,4-dihydroxymethylproline, 4,5-dihydroxyornithine and lipid | HMV CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, SMCHD1 | NPBWR1 1112/4885OPRD1 1144/4885OPRM1 533/4885 |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | NPBWR1 175/4885OPRD1 2888/4885OPRM1 3137/4885 |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | NPBWR1 175/4885OPRD1 2888/4885OPRM1 3137/4885 |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | NPBWR1 1042/4885OPRD1 2515/4885OPRM1 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.